A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs SRT 2104 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- 07 Nov 2011 Company added as trial sponsor as reported by European Clinical Trials Database record.
- 07 Nov 2011 Actual initiation date (Feb 2010) added as reported by European Clinical Trials Database record.
- 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.